Do you want to read an article? Please log in or register.
Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial
Thyroid
COMMENTED
Related content
COMMENTED
Thyroid
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
Lancet Diabetes Endocrinol.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A
doi: 10.1016/S2213-
Thyroid
Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer
Thyroid
Koehler VF, Berg E, Adam P, Weber GL, Pfestroff A, Luster M, Kutsch JM, Lapa C, Sandner B, Rayes N, Fuss CT, Kreissl M, Hoster E, Allelein S, Schott M, Todica A, Fassnacht M, Kroiss M, Spitzweg C
doi: 10.1089/thy.2021.0091
Thyroid
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Lancet Diabetes Endocrinol
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH
doi: 10.1016/S2213-8587(21)00120-0
Thyroid
Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness
Thyroid
Kang YE, Kim JM, Lim MA, Lee SE, Yi S, Kim JT, Oh C, Liu L, Jin Y, Jung SN, Won HR, Chang JW, Lee JH, Kim HJ, Koh HY, Jun S, Cho SW, Shong M, Koo BS
doi: 10.1089/thy.2020.0034
COMMENTED
Thyroid
Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Front Endocrinol (Lausanne)
Czarniecka A, Zeman M, Wozniak G, Maciejewski A, Stobiecka E, Chmielik E, Oczko-Wojciechowska M, Krajewska J, Handkiewicz-Junak D, Jarzab B
doi: 10.3389/fendo.2021.718833
Thyroid
Predictive impact of metastatic lymph node burden on distant metastasis across papillary thyroid cancer variants
Thyroid
Ho AS, Luu M, Shafqat I, Mallen-St Clair J, Chen MM, Chen Y, Jain M, Ali N, Patio C, Filarski C, Lin DC, Bankston H, Braunstein G, Sacks W, Zumsteg ZS
doi: 10.1089/thy.2021.0131
Obesity and Bariatric SurgeryThyroid
Does obesity cause thyroid cancer? A Mendelian randomization study
★ 1
Recommended by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Clin Endocrinol Metab.
Fussey JM, Beaumont RN, Wood AR, Vaidya B, Smith J, Tyrrell J
doi: 10.1210/clinem/dgaa250.
Glycemic Control
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
J Clin Oncol
Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, Nyman J, Abel E, Friesland S, Sjödin H, Carlsson H, Söderkvist K, Thomasson M, Zackrisson B, Nilsson P
doi: 10.1200/JCO.20.02072
RECOMMENDED
Thyroid
A THYROID GENETIC CLASSIFIER CORRECTLY PREDICTS BENIGN NODULES WITH INDETERMINATE CYTOLOGY: TWO-INDEPENDENT MULTICENTER, PROSPECTIVE VALIDATION TRIALS
★ 1
Recommended by
Prof. emer. Dr Ulrich Keller, Faculty Member
Thyroid.
Zafereo M, McIver B, Vargas S, Domínguez Ruiz-Tagle JM, Steward D, Holsinger FC, Kandil E, Williams MD, Cruz F, Loyola S, Solar A, Roa JC, Leon A, Droppelmann N, Arias T, Lobos M, Kong CS, Busaidy N, Grubbs EG, Graham PH, Stewart J, Tang A, Wang J, Orloff LA, Hernríquez-Henríquez M, Lagos M, Wohllk N, Diaz RE, Véliz J, Horvath E, Tala H, Pineda P, Arroyo P, Vasquez F, Osorio M, Schacter D, Franco C, Medina F, Traipe E, Marin L, Miranda G, Bruce E, Bracamonte Nole M, Mena N, Gonzalez H
doi: 10.1089/thy.2019.0490.